CDK1/2/5 blockade: killing two birds with one stone

Research output: Contribution to journalArticlepeer-review


Pancreatic ductal adenocarcinoma (PDAC) is an immune resistant tumor. We recently demonstrated that inhibiting CDK1/2/5 by dinaciclib not only blocks immune checkpoint expression, but also triggers histone-dependent immunogenic cell death. This dual mechanism turns immunologically “cold” tumor microenvironment into a “hot” one, improves overall survival rates in mouse PDAC models.

Original languageEnglish (US)
Article number1875612
Issue number1
StatePublished - 2021


  • Apoptosis
  • CDK
  • dinaciclib
  • histone
  • immune checkpoint
  • immunogenic cell death
  • immunotherapy
  • pancreatic cancer

ASJC Scopus subject areas

  • Immunology and Allergy
  • Immunology
  • Oncology

Fingerprint Dive into the research topics of 'CDK1/2/5 blockade: killing two birds with one stone'. Together they form a unique fingerprint.

Cite this